Adolor Corporation (NasdaqGM: ADLR) today announced that management will present at the Wedbush Securities 2011 Life Sciences Management Access Conference on Tuesday, August 16, 2011, at 1:15 P.M. Eastern Daylight Time. The conference is being held at the Le Parker Meridien, New York, NY.

Adolor’s presentation will be webcast live on the investor relations section of the Company’s website and will be archived for one week following the broadcast. To access the webcast, log onto the Company’s website at www.adolor.com and click on “Investor Insights,” then “Webcast.” Click on the link and follow the prompts for registration and access.

About Adolor

Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain and pain management products.

Adolor’s first approved product in the United States is ENTEREG® (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available for short-term use in hospitals registered under the E.A.S.E.® Program. For more information on ENTEREG, including its full prescribing information, visit www.ENTEREG.com. The Company currently co-promotes ENTEREG in collaboration with GSK.

The Company's lead development program compound is ADL5945, a novel mu opioid receptor antagonist being developed for chronic OIC that demonstrated statistically significant and clinically relevant efficacy in Phase 2 trials. The Company also has several earlier-stage compounds under development for the management of pain and CNS disorders.

For more information, visit www.adolor.com.

Copyright Business Wire 2010

If you liked this article you might like

Insiders Trading TXI, WFM, ADLR, TRS

Insiders Trading TXI, WFM, ADLR, TRS

10 Best-Performing Stocks Under $5 in 2011

ValueAct Buys $3.9M More of Immucor

ValueAct Buys $3.9M More of Immucor

Health Winners & Losers: Bristol-Myers

Health Winners & Losers: Bristol-Myers

Progenics Has a Few Reasons to Live

Progenics Has a Few Reasons to Live